Health Trials

Metastasis Castration Resistant Prostate Cancermcrpc

2

Review clinical trials related to Metastasis Castration Resistant Prostate Cancermcrpc. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

Response With Interim PSMA PET in Metastatic Castration-sensitive Prostate Cancer for Optimization of Adaptive Metastasis-directed Radiotherapy Delivery

The purpose of this study is to characterize the reduction in PSMA-avid tumor volume and metastasis-directed radiotherapy treatment intensity facilitated by PET PSMA-response adapted SABR for poly-metastatic castration sensitive prostate cancer.

Participants needed: 30
Trial details
Phase: Early Phase 1Age: 18+Biological sex: MaleType: InterventionalSponsor: University of Texas Southwestern Medical CenterUpdated: Jun 30, 2026Locations: 1
Eligibility criteria

History of pathologically confirmed prostate cancer. [+7]

Prior radiotherapy to any metastases currently targeted for therapy or overlappi... [+5]

Read more
Status: Recruiting

ARTEMIS-003: HS-20093 in Patients With Metastatic Castrate-resistant Prostate Cancer (mCRPC) and Advanced Solid Tumors

HS-20093 is a fully humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on solid tumor cells. The objectives of this study are to investigate the anti-tumor activity, safety and pharmacokinetics of HS-20093 in Chinese patients with metastasis Castration Resistant Prostate Cancer. This is a phase 2, open-label, multi-center study to evaluate the efficacy, safety, tolerability and pharmacokinetic (PK) of HS-20093 as a monotherapy in subjects with metastasis castration resistant prostate cancers (mCRPC) and other solid tumors.

Participants needed: 120
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Hansoh BioMedical R&D CompanyUpdated: Aug 20, 2024Locations: 15
Eligibility criteria

Men or women greater than or equal to 18 years. [+8]

Patients with BRCA and ATM mutation. [+21]

Read more